Targeting eosinophils: Severe asthma and beyond

Marco Caminati, Francesco Menzella, Lucia Guidolin, Gianenrico Senna

Research output: Contribution to journalReview article

Abstract

Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. However, non-negligible differences between asthma and other eosinophilic diseases, particularly in eosinophils homing (blood and/or tissues), target organs and thus clinical features, probably account for the different response to the same drug in different clinical conditions and highlights the need for tailoring the therapeutic approach by modulating the drug dose and/or by combination therapy with multiple drugs. The optimal safety and tolerability profile of anti-IL-5 drugs warrants further and larger experimental and real-life investigations, which are needed especially in the field of non-asthma eosinophilic diseases. This review aims at summarizing the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action. The current efficacy and safety evidence about eosinophils and IL-5 targeting molecules in asthma and in eosinophilic conditions beyond bronchi is also discussed.

Original languageEnglish
Article number21258
JournalDrugs in Context
Volume8
DOIs
Publication statusPublished - Jan 1 2019
Externally publishedYes

Fingerprint

Interleukin-5
Eosinophils
Asthma
Biological Products
Safety
Pharmaceutical Preparations
Interleukin-5 Receptors
Eosinophilic Esophagitis
Allergic Bronchopulmonary Aspergillosis
Hypereosinophilic Syndrome
Bronchi
Nose
Natural Killer Cells
Clinical Trials
Inflammation
Phenotype
Antibodies
Therapeutics
Research

Keywords

  • ABPA
  • Benralizumab
  • EGPA
  • Eosinophilic esophagitis
  • Eosinophilic inflammation
  • Mepolizumab
  • Reslizumab
  • Severe asthma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Caminati, M., Menzella, F., Guidolin, L., & Senna, G. (2019). Targeting eosinophils: Severe asthma and beyond. Drugs in Context, 8, [21258]. https://doi.org/10.7573/dic.212587

Targeting eosinophils : Severe asthma and beyond. / Caminati, Marco; Menzella, Francesco; Guidolin, Lucia; Senna, Gianenrico.

In: Drugs in Context, Vol. 8, 21258, 01.01.2019.

Research output: Contribution to journalReview article

Caminati, M, Menzella, F, Guidolin, L & Senna, G 2019, 'Targeting eosinophils: Severe asthma and beyond', Drugs in Context, vol. 8, 21258. https://doi.org/10.7573/dic.212587
Caminati M, Menzella F, Guidolin L, Senna G. Targeting eosinophils: Severe asthma and beyond. Drugs in Context. 2019 Jan 1;8. 21258. https://doi.org/10.7573/dic.212587
Caminati, Marco ; Menzella, Francesco ; Guidolin, Lucia ; Senna, Gianenrico. / Targeting eosinophils : Severe asthma and beyond. In: Drugs in Context. 2019 ; Vol. 8.
@article{9159911d2d014344bc22c5400ea6a9f7,
title = "Targeting eosinophils: Severe asthma and beyond",
abstract = "Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. However, non-negligible differences between asthma and other eosinophilic diseases, particularly in eosinophils homing (blood and/or tissues), target organs and thus clinical features, probably account for the different response to the same drug in different clinical conditions and highlights the need for tailoring the therapeutic approach by modulating the drug dose and/or by combination therapy with multiple drugs. The optimal safety and tolerability profile of anti-IL-5 drugs warrants further and larger experimental and real-life investigations, which are needed especially in the field of non-asthma eosinophilic diseases. This review aims at summarizing the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action. The current efficacy and safety evidence about eosinophils and IL-5 targeting molecules in asthma and in eosinophilic conditions beyond bronchi is also discussed.",
keywords = "ABPA, Benralizumab, EGPA, Eosinophilic esophagitis, Eosinophilic inflammation, Mepolizumab, Reslizumab, Severe asthma",
author = "Marco Caminati and Francesco Menzella and Lucia Guidolin and Gianenrico Senna",
year = "2019",
month = "1",
day = "1",
doi = "10.7573/dic.212587",
language = "English",
volume = "8",
journal = "Drugs in Context",
issn = "1745-1981",
publisher = "JUST Medical Media Limited",

}

TY - JOUR

T1 - Targeting eosinophils

T2 - Severe asthma and beyond

AU - Caminati, Marco

AU - Menzella, Francesco

AU - Guidolin, Lucia

AU - Senna, Gianenrico

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. However, non-negligible differences between asthma and other eosinophilic diseases, particularly in eosinophils homing (blood and/or tissues), target organs and thus clinical features, probably account for the different response to the same drug in different clinical conditions and highlights the need for tailoring the therapeutic approach by modulating the drug dose and/or by combination therapy with multiple drugs. The optimal safety and tolerability profile of anti-IL-5 drugs warrants further and larger experimental and real-life investigations, which are needed especially in the field of non-asthma eosinophilic diseases. This review aims at summarizing the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action. The current efficacy and safety evidence about eosinophils and IL-5 targeting molecules in asthma and in eosinophilic conditions beyond bronchi is also discussed.

AB - Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. However, non-negligible differences between asthma and other eosinophilic diseases, particularly in eosinophils homing (blood and/or tissues), target organs and thus clinical features, probably account for the different response to the same drug in different clinical conditions and highlights the need for tailoring the therapeutic approach by modulating the drug dose and/or by combination therapy with multiple drugs. The optimal safety and tolerability profile of anti-IL-5 drugs warrants further and larger experimental and real-life investigations, which are needed especially in the field of non-asthma eosinophilic diseases. This review aims at summarizing the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action. The current efficacy and safety evidence about eosinophils and IL-5 targeting molecules in asthma and in eosinophilic conditions beyond bronchi is also discussed.

KW - ABPA

KW - Benralizumab

KW - EGPA

KW - Eosinophilic esophagitis

KW - Eosinophilic inflammation

KW - Mepolizumab

KW - Reslizumab

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85070242149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070242149&partnerID=8YFLogxK

U2 - 10.7573/dic.212587

DO - 10.7573/dic.212587

M3 - Review article

AN - SCOPUS:85070242149

VL - 8

JO - Drugs in Context

JF - Drugs in Context

SN - 1745-1981

M1 - 21258

ER -